Quality maturity is useful as a buyer’s decision lens because a project can appear compliant on paper while its governance remains unclear when a deviation, material change, method-transfer gap or supply interruption occurs. The question is not whether a facility has been “rated mature.” The question is whether its proposed operating system can be understood, tested and governed for the defined project.
1. Separate baseline compliance from operating maturity
FDA describes its Quality Management Maturity program as encouraging practices that go beyond current good manufacturing practice requirements, including a quality culture, continual improvement and resilience of supply. That does not create a new universal qualification standard for selecting a partner. It does, however, clarify why a sponsor should distinguish baseline compliance from the ability to manage quality decisions over time.
For selection purposes, ask two separate questions: What regulatory and quality evidence is relevant to the defined project? and How are quality issues governed when the initial plan changes? The answers should be specific to the legal entity, manufacturing site, dosage form, product route, lifecycle stage and intended market.
2. Ask five evidence-based questions
Question 1: How are quality issues escalated and reviewed?
Request a clear non-confidential explanation of the project governance model: quality-unit involvement, decision authorities, escalation path, management-review cadence and how a sponsor is informed. ICH Q10 describes management review and timely escalation as part of a pharmaceutical quality system. For a transfer or scale-up project, the practical issue is whether the right functions can make and document decisions at the right time.
Question 2: What does the investigation and CAPA route look like?
Do not ask only whether a CAPA procedure exists. Ask how deviations, complaints, non-conformances and audit observations move from detection to root-cause assessment, action, effectiveness review and sponsor communication. The evidence level should be proportionate to the project and handled under appropriate confidentiality controls.
Question 3: How is change control connected to the product and the filing?
A transfer frequently exposes differences in equipment, materials, analytical methods, utilities, scale or operating practice. ICH Q10 describes a risk-based change-management system that evaluates proposed changes against current product and process knowledge and, where relevant, the marketing authorisation. A useful due-diligence discussion therefore maps what may change, who evaluates it, what evidence is required, who approves it and how the regulatory impact is assessed.
Question 4: Is technology-transfer governance explicit?
Technology transfer is not only document receipt. It is the controlled movement and use of product and process knowledge. A receiving site should be able to explain the transfer plan, gap-assessment route, analytical-method readiness, issue log, responsibilities, decision gates and how knowledge from scale-up is fed back into the control strategy. If that route is vague, the project label may be concealing an unresolved development or governance gap.
Question 5: How is quality linked to reliable supply?
FDA’s QMM materials connect mature quality practices with resilience and reliable supply. A sponsor should not infer performance, capacity or continuity from that policy objective. Instead, ask concrete project questions: What are the agreed communication routes for quality-impacting events? How are materials, testing, release, storage and change decisions coordinated? What evidence would trigger a hold, escalation or re-planning decision?
3. Put the questions into the right sequence
- Public fit screen: legal entity and site, public dosage-form scope, intended market, lifecycle stage and a non-confidential project objective.
- Mutual confidentiality and scope: agree what may be exchanged and the purpose of the review before sharing detailed formulae, process parameters, dossiers, patient information or trade secrets.
- Project-specific due diligence: assess technical, analytical, quality, regulatory, capacity and commercial fit; a general quality-system discussion cannot replace this step.
- Written operating model: translate agreed responsibilities, change routes, communications and records into appropriate project and quality agreements.
Frequently asked questions
Does quality management maturity mean a CMO/CDMO is certified or approved?
No. It is a decision framework, not a certification, approval, inspection result or conclusion about a facility.
What can be shared before an NDA?
A first contact should normally be limited to non-confidential facts such as dosage form, presentation, project stage, target market, requested model, intended timing and the decision to be made. Use controlled disclosure after a mutual NDA and review plan are in place.
Can a quality agreement replace a CMO/CDMO audit?
No. A quality agreement documents responsibilities and communication routes; it does not replace assessment of the site, product, process, analytics, quality system and target-market fit.
Why is management review relevant to technology transfer?
Transfer creates cross-functional decisions and changes. Clear escalation, management review and change governance help determine how issues are assessed, documented and resolved through transfer and scale-up.
Authoritative sources
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice, an audit conclusion or a statement about any facility. Project requirements must be confirmed with the responsible parties and applicable authorities.